PL4034661T3 - Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem - Google Patents

Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem

Info

Publication number
PL4034661T3
PL4034661T3 PL21715779.1T PL21715779T PL4034661T3 PL 4034661 T3 PL4034661 T3 PL 4034661T3 PL 21715779 T PL21715779 T PL 21715779T PL 4034661 T3 PL4034661 T3 PL 4034661T3
Authority
PL
Poland
Prior art keywords
treatment
aav vectors
coronavirus diseases
coronavirus
diseases
Prior art date
Application number
PL21715779.1T
Other languages
English (en)
Inventor
Elisabeth ZEISBERG
Xingbo XU
Michael Zeisberg
Gerd Hasenfuss
Xiaoying TAN
Original Assignee
Zeisberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeisberg filed Critical Zeisberg
Publication of PL4034661T3 publication Critical patent/PL4034661T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL21715779.1T 2020-04-08 2021-03-11 Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem PL4034661T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063006996P 2020-04-08 2020-04-08
PCT/EP2021/056221 WO2021204492A1 (en) 2020-04-08 2021-03-11 All-in-one aav vectors for treating coronavirus-induced diseases

Publications (1)

Publication Number Publication Date
PL4034661T3 true PL4034661T3 (pl) 2024-03-18

Family

ID=75339666

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21715779.1T PL4034661T3 (pl) 2020-04-08 2021-03-11 Wektory aav typu „wszystko w jednym” do leczenia chorób wywołanych koronawirusem

Country Status (11)

Country Link
US (1) US20230242914A1 (pl)
EP (1) EP4034661B1 (pl)
JP (1) JP7756284B2 (pl)
CN (1) CN115667512A (pl)
AU (1) AU2021253344B2 (pl)
ES (1) ES2967509T3 (pl)
HR (1) HRP20240099T8 (pl)
HU (1) HUE065161T2 (pl)
PL (1) PL4034661T3 (pl)
RS (1) RS65372B1 (pl)
WO (1) WO2021204492A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN119256088A (zh) * 2022-02-16 2025-01-03 新加坡科技研究局 预防或治疗受试者中的rna病毒感染的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014207153A1 (de) 2014-04-14 2015-10-15 Rabea Hinkel AAV-Vektoren für vaskuläre Gentherapie in koronarer Herzerkrankung und peripherer Ischämie
CN110959039B (zh) * 2017-03-15 2025-03-14 博德研究所 新型cas13b直向同源物crispr酶和系统
US10476825B2 (en) * 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
US20230174975A1 (en) * 2020-03-13 2023-06-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting

Also Published As

Publication number Publication date
HRP20240099T1 (hr) 2024-05-24
JP7756284B2 (ja) 2025-10-20
CN115667512A (zh) 2023-01-31
ES2967509T3 (es) 2024-04-30
EP4034661C0 (en) 2023-09-06
AU2021253344B2 (en) 2025-08-28
CA3174832A1 (en) 2021-10-14
WO2021204492A1 (en) 2021-10-14
AU2021253344A1 (en) 2022-12-01
JP2023520814A (ja) 2023-05-19
RS65372B1 (sr) 2024-04-30
US20230242914A1 (en) 2023-08-03
EP4034661A1 (en) 2022-08-03
HRP20240099T8 (hr) 2024-06-21
EP4034661B1 (en) 2023-09-06
HUE065161T2 (hu) 2024-05-28

Similar Documents

Publication Publication Date Title
IL279918A (en) Gene therapy vectors for treatment of danon disease
IL285238A (en) Gene therapy vectors for treatment of danon disease
EP3898979A4 (en) Amyloid precursor protein (app) rnai agent compositions and methods of use thereof
EP3813634A4 (en) ARTICULATING MEDICAL INSTRUMENTS
EP3861121A4 (en) RAAV VECTORS FOR THE TREATMENT OF GM1 AND GM2 GANGLIOSIDOSIS
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
IL279786A (en) Prophylactic or therapeutic agent for spinal muscular atrophy
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL279810A (en) Heteroaryl-converted sulfonamide compounds and their use as medicinal agents
SG11202012289UA (en) Kdm1a inhibitors for the treatment of disease
IL288940A (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
IL281244A (en) Combination therapy for the treatment of liver disease
PT3990005T (pt) Cistationina beta-sintetase peguilada para terapia enzimática para tratamento de homocistinúria
EP4179098A4 (en) GENE THERAPY FOR STXBP1 ENCEPHALOPATHY
EP4051324A4 (en) GENE THERAPY VECTORS
EP4048794A4 (en) Triple function adeno-associated virus (aav) vectors for the treatment of c9orf72 associated diseases
IL309468A (en) Biomarkers for alzheimer's disease treatment
IL312851A (en) Sulfonamide compounds for the treatment of neurological conditions
EP4203928A4 (en) Inhalable therapeutic agents
PL3886799T3 (pl) Kompozycje do leczenia utraty włosów
IL281083A (en) Adeno-associated viral vectors for the treatment of best disease
EP4021858A4 (en) TREATMENT OF AZOLES
EP4021369A4 (en) Medical devices for continuous delivery of therapeutic agents
JP1779364S (ja) ペーシェントパッド
EP3927328A4 (en) INHALABLE THERAPEUTIC AGENT